-
公开(公告)号：US12235278B2
公开(公告)日：2025-02-25
申请号：US17270830
申请日：2019-08-23
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Robert Flaumenhaft , David Barrios , Secil Koseoglu
Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
-
公开(公告)号：US12181554B2
公开(公告)日：2024-12-31
申请号：US18067489
申请日：2022-12-16
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Reza Nezafat , Rui Guo
IPC: G01R33/56 , G01R33/50 , G06N3/0455 , G06N3/08
Abstract: A system for quantitative parameter mapping using magnetic resonance (MR) image includes an input for receiving a plurality of weighted MR images of a subject and a corresponding at least one imaging parameter for the plurality of weighted MR images, and a quantitative parameter mapping neural network coupled to the input and configured to estimate at least one tissue parameter and generate at least one quantitative map for the at least one tissue parameter based on the plurality of weighted MR images of the subject and the corresponding at least one imaging parameter. The quantitative parameter mapping neural network can be trained using a set of training data utilizing at least one confounder for the quantification of the at least one tissue parameter. The system can further include a display coupled to the quantitative parameter mapping neural network to display the at least one quantitative map.
-
公开(公告)号：US12168700B2
公开(公告)日：2024-12-17
申请号：US18459892
申请日：2023-09-01
Inventor： James D. McCully , Sidney Levitsky , Douglas B. Cowan , Pedro J. del Nido , Sitaram M. Emani
IPC: C07K16/46 , A61B6/42 , A61B6/50 , A61B8/08 , A61K9/00 , A61K35/12 , A61K35/28 , A61K35/34 , A61K39/00 , A61K47/69 , A61K49/00 , A61K49/18 , A61K51/04 , A61K51/12 , C12N15/11
Abstract: The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.
-
4.发明公开公开(公告)号：US20240342507A1
公开(公告)日：2024-10-17
申请号：US18133962
申请日：2023-04-12
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Ammar Sarwar , Joseph Ring
CPC classification number: A61N5/1071 , A61K51/1251 , A61N5/1002 , A61N5/1007 , G16H10/60 , A61N2005/1021
Abstract: A microsphere delivery apparatus providing real-time measuring of delivered radioactivity during medical procedures utilizing radioactive emitting microspheres wherein an administration housing includes a holder to receive a vial containing microspheres for delivery to a patient, a detector holder to receive a radiation detector and a delivery tube assembly for transporting fluid containing the microspheres.
-
公开(公告)号：US20240158514A1
公开(公告)日：2024-05-16
申请号：US18489525
申请日：2023-10-18
Applicant: Novartis AG , Beth Israel Deaconess Medical Center, Inc.
Inventor： Anthony ROSENZWEIG , Jason D. ROH , David J. GLASS
CPC classification number: C07K16/2863 , A61P9/04 , C07K2317/76
Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
-
Patent Agency Ranking
公开(公告)号：US20240158466A1
公开(公告)日：2024-05-16
申请号：US18272092
申请日：2022-01-13
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Elliot Chaikof , Richard D. Cummings
IPC: C07K14/705 , A61K47/54 , A61K47/60 , A61P7/02 , C07K1/107
CPC classification number: C07K14/70564 , A61K47/549 , A61K47/60 , A61P7/02 , C07K1/1077
Abstract: This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide and a polyethylene glycol (PEG) moiety. In some embodiments, the disclosure relates to uses of the PEGylated glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.
-
公开(公告)号：US11926824B2
公开(公告)日：2024-03-12
申请号：US16827343
申请日：2020-03-23
Applicant: Board of Regents, The University of Texas System , Beth Israel Deaconess Medical Center, Inc.
Inventor： Raghu Kalluri , Sónia Melo
IPC: C12N15/113 , A61K39/00 , C07K14/47 , C07K16/40 , C12Q1/6886 , G01N33/574 , G16B20/00
CPC classification number: C12N15/113 , C07K14/4703 , C07K16/40 , C12Q1/6886 , G01N33/57488 , G16B20/00 , A61K2039/505 , C12N2310/14 , C12N2310/141 , C12Q2600/158 , C12Q2600/178 , G01N2333/4704 , Y02A90/10
Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
-
公开(公告)号：US11795213B2
公开(公告)日：2023-10-24
申请号：US15666030
申请日：2017-08-01
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Detlef Schuppan , Yvonne Junker , Towia Aron Libermann , Simon T. Dillon
CPC classification number: C07K16/18 , C07K16/16 , A61K2039/505 , C07K2317/76 , C12N15/8218 , C12N15/8245
Abstract: The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM1 6, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.
-
公开(公告)号：US11773142B2
公开(公告)日：2023-10-03
申请号：US16772045
申请日：2018-12-11
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Dan H. Barouch , Peter Abbink , Mark Justin Iampietro , Menzo J. E. Havenga
IPC: C07K14/075 , A61K35/761 , A61K39/235 , A61K31/7088 , C07K14/54 , C12N15/861
CPC classification number: C07K14/075 , A61K31/7088 , A61K35/761 , A61K39/235 , C07K14/5425 , C12N15/861
Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
-
公开(公告)号：US20230303674A1
公开(公告)日：2023-09-28
申请号：US18332068
申请日：2023-06-09
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Rami BURSTEIN
CPC classification number: C07K16/18 , A61P25/06 , A61K39/3955 , A61K9/0019 , A61P43/00 , A61P29/00 , C07K2317/76 , C07K2317/51 , C07K2317/515 , A61K2039/505
Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
-
-
-
-
-
-
-
-
-
Search Results
527
records
(took 0.039 seconds)
